Sinopharm to Begin Phase 3 Trial of its COVID-19 Vaccine Candidate in Peru

Sinopharm has announced that it will launch another phase 3 trial of its experimental COVID-19 vaccine candidate, this time in Peru, following a greenlight from the Peruvian health regulator.

The state-owned Beijing-based company is currently conducting a late-stage trial in the United Arab Emirates that is studying two formulations of the vaccine in 15,000 participants and a separate phase 3 trial in Bahrain that will enroll 6,000 participants.

Sinopharm previously announced that its experimental COVID-19 vaccine was found to be safe and generated high levels of antibodies in a phase 1/2 trial in China.